8-K: Scorpius Holdings Reports 359% Revenue Increase and 34% Operating Expense Reduction in Q1 2024

Scorpius Holdings, Inc. reported a significant 359% year-over-year increase in revenue for the first quarter of 2024, accompanied by a 34% reduction in operating expenses.

Summary

• Scorpius Holdings, Inc. reported a 359% year-over-year revenue increase for Q1 2024, reaching $3.5 million, up from $0.7 million in Q1 2023.
• The company also reduced operating expenses by 34% compared to the same period last year.
• The increase in revenue is attributed to expanded biomanufacturing operations and service offerings.
• Cost of revenues increased due to expanded service offerings and completed milestone work on multiple CDMO contracts.
• Research and development expenses decreased to $3.9 million from $6.3 million in the prior year.
• Selling, general, and administrative expenses decreased by $1.5 million, primarily due to reductions in marketing, consultant labor, and stock-based compensation.
• The net loss attributable to Scorpius was reduced to $4.4 million, or $0.16 per share, from $12.8 million, or $0.49 per share, in Q1 2023.
• As of March 31, 2024, the company had $1.7 million in cash, cash equivalents, and short-term investments.
• On May 16, 2024, Scorpius completed a public offering, raising approximately $6.0 million in gross proceeds.

Sentiment

Score: 7

Explanation: The significant revenue growth and cost reductions are positive indicators. However, the company still reported a net loss and had relatively low cash reserves before the recent capital raise, tempering the overall sentiment.

Positives

• The company is successfully executing its strategy to enhance revenue and reduce costs.
• The company has a highly scalable business model.
• There are significant industry-wide capacity shortages, which benefits Scorpius.
• The company anticipates achieving meaningful operating leverage by increasing utilization of its San Antonio campus.

Negatives

• The company experienced a net loss of $4.4 million in Q1 2024.
• The company had only $1.7 million in cash, cash equivalents, and short-term investments as of March 31, 2024.

Risks

• The company may face challenges in expanding its large molecule biomanufacturing CDMO services and attracting new customers.
• The company may not be able to capture a meaningful market share or become cash flow positive.
• The company has financing needs and may need to raise additional capital.
• The company may face challenges in leveraging fixed costs and achieving long-term profitability.
• The company may face challenges in obtaining regulatory approvals or complying with ongoing regulatory requirements.

Future Outlook

The company aims to become cash flow positive in the near future by enhancing revenue and reducing costs. They believe their business model is poised to generate meaningful cash flow as they continue to grow sales and increase utilization of their San Antonio campus. They are also optimistic about the future due to industry-wide capacity shortages and their growing revenue backlog.

Management Comments

• We are successfully executing our strategy to enhance revenue and reduce costs as we seek to become cash flow positive in the near future.
• This quarter is indicative of this goal as we achieved a 359% increase in revenue while reducing operating expenses by 34% over the same period last year.
• We believe this performance reinforces the growing demand for our services and our prudent financial management.
• Moreover, we have built a highly scalable business model poised to generate meaningful cash flow as we continue to grow our sales and increase utilization of our state-of-the-art San Antonio campus, which we anticipate will allow us to achieve meaningful operating leverage.
• We are very confident that the future for Scorpius is brighter than ever, with significant industry-wide capacity shortages, and our growing revenue backlog, which stood at $10.8 million as of March 31, 2024.

Industry Context

This announcement highlights Scorpius' efforts to capitalize on the growing demand for CDMO services in the biopharmaceutical industry. The company is positioning itself to benefit from industry-wide capacity shortages and is focusing on expanding its biomanufacturing operations.

Comparison to Industry Standards

• Compared to other CDMOs like Lonza, Catalent, and Boehringer Ingelheim, Scorpius is a smaller player but is growing rapidly.
• Lonza reported 2023 revenues of CHF 6.7 billion, Catalent reported 2023 revenues of $4.83 billion and Boehringer Ingelheim reported 2023 revenues of EUR 25.6 billion, significantly larger than Scorpius' current revenue run rate.
• However, Scorpius' 359% year-over-year revenue growth in Q1 2024 is significantly higher than the average growth rates of these larger, established CDMOs.
• For example, Lonza's Biologics segment grew 12.7% in 2023, while Catalent's Biologics segment declined 11% in their most recent fiscal year.
• Scorpius' focus on biologics and cell therapy manufacturing aligns with industry trends, as these areas are experiencing high growth.
• The company's new, purpose-built facilities in San Antonio are a competitive advantage compared to some older facilities operated by competitors.

Related Party Transactions

• Change in fair value of contingent earn-out receivable, related party, was $1.0 million for the three months ended March 31, 2024.
• Change in fair value of convertible promissory note, related party was $0.1 million for the three months ended March 31, 2024.

Stakeholder Impact

• Shareholders may benefit from the company's revenue growth and progress towards profitability.
• Employees may benefit from the company's expansion and potential for future growth.
• Customers may benefit from the company's expanded service offerings and increased capacity.

Next Steps

• Hold the 2024 Annual Meeting of Stockholders on August 2, 2024.
• Continue to grow sales and increase utilization of the San Antonio campus.
• Work towards becoming cash flow positive.

Key Dates

Keywords

CDMO, biomanufacturing, contract development and manufacturing organization, biologics, cell therapy, pharmaceutical, biotech, process development, analytical testing, San Antonio, capacity shortages, revenue backlog